Shots:

• The approval is based on 12 clinical trials results assessing TPOXX (tecovirimat) in 700 patients- demonstrating no adverse effects
• ’ TPOXX (tecovirimat) receives 17-0 votes from FDA’s Antimicrobial Drug Advisory Committee on 05 May- 2018 and also received FDA’s FT- PR & ODD in Dec 2005- 08 Dec- 2017- 07 Jun- 2018 respectively
• TPOXX (tecovirimat) also known as ST-246 is a PO & IV respectively for treating smallpox- developed in collaboration with the US Department of Health & Human Services’ BARDA

Ref: Siga | Image: MacAndrews & Forbes